Breakthrough Device For Pediatric Sleep Apnea Approved By FDA

2 min read | September 18, 2024 10:38 AM EDT | By Team Kalkine Media

Google News:

Breakthrough Device For Pediatric Sleep Apnea Approved By FDA — Image source: Shutterstock

Recent News

Sienna Senior Living Benefits From Canada’s Growing Care Demand

WELL Health Keeps Clinics Busy As Healthcare Demand Grows

Lundin Mining’s Copper Strategy Takes Centre Stage On TSX

Canadian Cannabis Stocks Face A New Strategy Test

Make Kalkine Media
My Trusted Source

Vivos Therapeutics has announced the receipt of US Food and Drug Administration (FDA) approval for its oral medical device designed to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17. This innovative device offers a non-invasive, orthodontic-based treatment option that differs from traditional methods such as adenotonsillectomy, which may not always yield long-term success. This advancement marks a significant development in the healthcare sector.

FDA Approval Marks a Milestone for Pediatric Sleep Apnea Treatment

Pediatric obstructive sleep apnea is linked to several health conditions, including attention deficit hyperactivity disorder (ADHD), asthma, and obesity. The FDA approval represents a significant milestone, as it is the first instance of an oral medical device being authorized for the treatment of moderate to severe OSA in children. The approval was granted following a rigorous multi-site, international study involving pediatric patients.

Study Results Highlight Device Efficacy and Safety

The study demonstrated a notable 62.7% reduction in the apnea-hypopnea index (AHI) and confirmed the device's safety. This substantial improvement in OSA symptoms underscores the device's effectiveness as a viable alternative to conventional treatments. The results contribute to a series of recent regulatory successes for Vivos Therapeutics (NASDAQ:VVOS), reinforcing the credibility and potential of its technology.

Strategic Business Model Expansion to Enhance Market Reach

According to Vivos Therapeutics CEO Kirk Huntsman, this FDA clearance opens new market opportunities and directly addresses the needs of children affected by sleep-related breathing disorders. The company's new marketing and distribution model, which involves partnerships with medical and dental professionals, is expected to enhance the reach and impact of their treatment solutions. Huntsman highlighted that the strategic shift towards collaborating with a broader range of healthcare providers is anticipated to drive further growth and expand the company's patient base.

Growing Body of Research and Regulatory Success

Huntsman emphasized that this regulatory success reflects the ongoing research and validation of Vivos Therapeutics' technology. The recent alliance-based marketing approach is poised to broaden the scope of patient care, potentially including multiple family members across various age groups. The company's efforts to expand beyond traditional dental practices and engage with medical specialists, functional medicine doctors, and other sleep-related healthcare practitioners are expected to positively influence case starts, revenue growth, and overall financial performance.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.